GHR 106-CAR-T
Alternative Names: CHR-106-CAR-T; GHR-106-CAR-TLatest Information Update: 28 Jul 2023
At a glance
- Originator Protheragen
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Ovarian cancer
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for preclinical development in Ovarian-cancer in USA (Parenteral)
- 13 Jun 2019 GHR 106-CAR-T is available for licensing as of 13 Jun 2019. https://www.protheragen.com/ghr106-car-t.html
- 13 Jun 2019 Protheragen has patent protection for GHR 106-CAR-T in USA and China before June 2019 (Protheragen website, June 2019).